Charles River Laboratories International, Inc. $CRL Shares Bought by QRG Capital Management Inc.

QRG Capital Management Inc. grew its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 39.8% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 2,177 shares of the medical research company’s stock after purchasing an additional 620 shares during the period. QRG Capital Management Inc.’s holdings in Charles River Laboratories International were worth $330,000 at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. Teacher Retirement System of Texas bought a new position in Charles River Laboratories International during the first quarter valued at about $1,231,000. Mirae Asset Global Investments Co. Ltd. increased its stake in Charles River Laboratories International by 15.4% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,118 shares of the medical research company’s stock worth $952,000 after purchasing an additional 817 shares in the last quarter. Janney Montgomery Scott LLC boosted its position in Charles River Laboratories International by 13.1% during the 1st quarter. Janney Montgomery Scott LLC now owns 44,500 shares of the medical research company’s stock worth $6,698,000 after acquiring an additional 5,148 shares during the period. GAMMA Investing LLC boosted its position in Charles River Laboratories International by 61.6% during the 1st quarter. GAMMA Investing LLC now owns 1,398 shares of the medical research company’s stock worth $210,000 after acquiring an additional 533 shares during the period. Finally, Concurrent Investment Advisors LLC acquired a new stake in Charles River Laboratories International during the 1st quarter worth about $213,000. Institutional investors own 98.91% of the company’s stock.

Charles River Laboratories International Price Performance

Shares of CRL stock opened at $167.17 on Friday. The stock’s fifty day simple moving average is $159.23 and its 200 day simple moving average is $147.55. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.36 and a quick ratio of 1.10. The firm has a market cap of $8.23 billion, a price-to-earnings ratio of -125.69, a P/E/G ratio of 4.47 and a beta of 1.50. Charles River Laboratories International, Inc. has a one year low of $91.86 and a one year high of $230.02.

Charles River Laboratories International (NYSE:CRL) last announced its quarterly earnings results on Wednesday, August 6th. The medical research company reported $3.12 EPS for the quarter, beating the consensus estimate of $2.50 by $0.62. The business had revenue of $1.03 billion for the quarter, compared to analyst estimates of $983.76 million. Charles River Laboratories International had a positive return on equity of 15.74% and a negative net margin of 1.69%.Charles River Laboratories International’s quarterly revenue was up .6% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.80 EPS. On average, analysts expect that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research firms have recently weighed in on CRL. Barclays raised Charles River Laboratories International from an “equal weight” rating to an “overweight” rating and raised their price target for the stock from $165.00 to $195.00 in a research note on Thursday, October 2nd. Jefferies Financial Group raised Charles River Laboratories International from a “hold” rating to a “buy” rating and lifted their price target for the stock from $142.00 to $195.00 in a research report on Tuesday, September 9th. William Blair upgraded Charles River Laboratories International from a “market perform” rating to an “outperform” rating in a research report on Monday, October 6th. Wall Street Zen cut Charles River Laboratories International from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, October 7th. Finally, JPMorgan Chase & Co. boosted their price objective on Charles River Laboratories International from $145.00 to $160.00 and gave the company a “neutral” rating in a research report on Thursday, August 7th. Eight equities research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $179.93.

Insider Buying and Selling

In other Charles River Laboratories International news, EVP Joseph W. Laplume sold 800 shares of the business’s stock in a transaction on Monday, August 18th. The stock was sold at an average price of $157.60, for a total value of $126,080.00. Following the transaction, the executive vice president owned 24,116 shares of the company’s stock, valued at approximately $3,800,681.60. The trade was a 3.21% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 1.30% of the company’s stock.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).